Pacira BioSciences (PCRX)
Develops non-opioid pain and musculoskeletal treatments built on a liposome drug-delivery platform.
$24.70
After hours+0.03 (+0.12%)
At close$24.67(+2.32%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 164 | 181 | 167 | 178 | 169 | 187 | 169 | 181 | 180 | 197 | 177 | 192 |
| Cost of revenue | 40 | 48 | 47 | 44 | 39 | 40 | 34 | 41 | 34 | 40 | 36 | 44 |
| Gross profit | 124 | 134 | 120 | 134 | 130 | 147 | 135 | 140 | 145 | 157 | 141 | 148 |
| 106 | 100 | 106 | 106 | 269 | 123 | 133 | 132 | 139 | 153 | 136 | 144 | |
| Research & development | 21 | 19 | 18 | 20 | 19 | 24 | 25 | 28 | 26 | 37 | 28 | 30 |
| 68 | 66 | 72 | 68 | 74 | 80 | 87 | 89 | 92 | 102 | 94 | 92 | |
| Selling & marketing | 38 | 36 | 39 | 39 | 43 | 50 | 56 | 51 | 58 | 62 | 58 | 0 |
| General & administrative | 30 | 30 | 33 | 29 | 31 | 29 | 31 | 38 | 33 | 40 | 36 | 92 |
| Other expenses | 18 | 15 | 16 | 17 | 176 | 19 | 21 | 15 | 21 | 14 | 14 | 22 |
| Operating income | 18 | 33 | 13 | 28 | −140 | 25 | 2 | 8 | 6 | 3 | 5 | 4 |
| −1 | 1 | 0 | 8 | 1 | 1 | 7 | −10 | 3 | −3 | 0 | −2 | |
| Interest income | 3 | 3 | 4 | 5 | 5 | 6 | 7 | 5 | 9 | 2 | 2 | 2 |
| Interest expense | 3 | 3 | 3 | 3 | 5 | 4 | 5 | 5 | 4 | 3 | 3 | 4 |
| Other non-operating income | −2 | −3 | −3 | −11 | −5 | −5 | −10 | 7 | −7 | −1 | −4 | 0 |
| Income before tax | 17 | 34 | 14 | 37 | −139 | 26 | 9 | −2 | 10 | 1 | 5 | 3 |
| Income tax expense | 6 | 9 | 5 | 18 | 5 | 9 | 4 | 3 | 4 | −1 | 2 | −2 |
| Net income from continuing operations | 11 | 25 | 9 | 19 | −143 | 16 | 5 | −5 | 5 | 2 | 3 | 5 |
| Net income | 11 | 25 | 9 | 19 | −143 | 16 | 5 | −5 | 5 | 2 | 3 | 5 |
| EPS, basic | $0.23 | $0.54 | $0.19 | $0.41 | −$3.11 | $0.35 | $0.10 | −$0.11 | $0.12 | $0.04 | $0.07 | $0.12 |
| EPS, diluted | $0.23 | $0.48 | $0.19 | $0.39 | −$3.11 | $0.34 | $0.10 | −$0.11 | $0.12 | $0.04 | $0.07 | $0.12 |
| Weighted average shares, basic | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 45 | 44 | 42 | 40 | 39 |
| Weighted average shares, diluted | 52 | 52 | 52 | 51 | 46 | 49 | 47 | 45 | 44 | 43 | 41 | 40 |
| EBITDA | 38 | 55 | 35 | 59 | −115 | 51 | 34 | 29 | 34 | 25 | 30 | 26 |
| Depreciation & amortization | 18 | 18 | 18 | 19 | 20 | 21 | 21 | 27 | 21 | 21 | 21 | 21 |
| EBIT | 19 | 36 | 16 | 40 | −135 | 29 | 12 | 2 | 13 | 4 | 8 | 4 |